Abstract

• Objectives
  We studied the open clinical trial to evaluate the efficacy and safety of TAGOCIN®, teicoplanin, glycopeptide anti microbial agent, which was manufactured in one Korean pharmacy.
• Methods
  We selected 15 patients hospitalized with presumed or proven infection due to gram positive organism, judged to require glycopeptiede and administered by intravenous bolus injection at a dose of 200mg TAGOCIN® per day. The efficacy was assessed by bacteriological result, clinical symptom and radiological change.
• Results
  Mean age of 15 patients treated is 66. 13 cases were lower respiratory tract infection, I case was urinary tract infection and I case was soft tissue infection. Gram positive organism was isolated in Seven samples of five patients, and at four patients of them, gram positive organism were eliminated. During treatment, one patients liver enzyme elevated mildly.
• Conclusion
  TAGOCIN® is an effective and tolerated antibiotics against gram positive organism in severe infected patients.
• Keywords: Teicoplanin; TAGOCID®; Methicillin resistant staphlococcus aureus(MRSA)